Propionyl-L-carnitine

Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis[1][2][3][4][5][6][7][8][9][10].

Product Specifications

CAS Number

[20064-19-1]

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Akt; AMPK; Apoptosis; Bcl-2 Family; Endogenous Metabolite; NF-κB; NO Synthase; Src; Survivin

Type

Peptides

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/propionyl-l-carnitine.html

Purity

95.0

Solubility

H2O : 125 mg/mL (ultrasonic)

Smiles

CCC(O[C@@H](C[N+](C)(C)C)CC([O-])=O)=O

Molecular Formula

C10H19NO4

Molecular Weight

217.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Victor Kamoen, et al. Propionyl-L-carnitine for intermittent claudication. Cochrane Database Syst Rev. 2021 Dec 26;12 (12) :CD010117.|[2]Ning WH, et al. Propionyl-L-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases. Vascul Pharmacol. 2013 Sep-Oct;59 (3-4) :76-82.|[3]Orlandi A, et al. Propionyl-L-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intimal smooth muscle cells by modulating nuclear factor-kappaB activity. J Biol Chem. 2007 Feb 16;282 (7) :4932-4942. |[4]Scioli MG, et al. Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction. PLoS One. 2015 Oct 16;10 (10) :e0140697.|[5]Mister M, et al. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int. 2002 Mar;61 (3) :1064-78.|[6]Mingorance C, et al. Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity. PLoS One. 2012;7 (3) :e34268. |[7]Scioli MG, et al. Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature. Clin Transl Gastroenterol. 2014 Mar 20;5 (3) :e55.|[8]Alvarez de Sotomayor M, et al. Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res. 2007;44 (5) :354-64.|[9]Al-Majed AA, et al. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006 Mar;53 (3) :278-86.|[10]Mingorance C, et al. Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats. Br J Nutr. 2009 Oct;102 (8) :1145-53.